Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has acquired TREK Diagnostic Systems, a global provider of microbiology solutions, including blood culture, microorganism identification and antibiotic susceptibility testing (AST) products, from Magellan Biosciences. Based near Cleveland, Ohio, the company had full year revenue in 2010 of $34 million and has 150 employees.
“Advances in automation and the development of more rapid and reliable tests enable us to provide our customers with improvements in productivity and efficiency that are critical when responding to increasingly complex microbiological threats to human health.”
"The range of products manufactured by TREK ideally complements our existing portfolio of microbiological testing technologies," said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. "Advances in automation and the development of more rapid and reliable tests enable us to provide our customers with improvements in productivity and efficiency that are critical when responding to increasingly complex microbiological threats to human health."
TREK Diagnostic Systems currently serves pharmaceutical and clinical laboratory markets and will be integrated into Thermo Fisher's Analytical Technologies Segment.
Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies